Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans.
about
Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China.Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus.In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus.Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populationsAntigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins.Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition.Purified viral neuraminidase vaccine to control influenza.Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses.Pregnancy Does Not Attenuate the Antibody or Plasmablast Response to Inactivated Influenza VaccineGenetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolutionPurified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.Isolation of immunogenic neuraminidases of human influenza viruses by a combination of genetic and biochemical proceduresMicroneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement.Antibody Responses to Trivalent Inactivated Influenza Vaccine in Health Care Personnel Previously Vaccinated and Vaccinated for The First Time.Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins.Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation.Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system.Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry.Recent contributions of molecular biology to the clinical virology of myxoviruses.In pursuit of influenza: Fort Monmouth to Valhalla (and back).VaxArray potency assay for rapid assessment of "pandemic" influenza vaccines
P2860
Q30373917-12AEAAF9-4980-4A26-80A5-7E1A21F708A7Q30400114-D33DE5E0-FB03-431F-9302-CD8C047FF558Q30407851-30D4EE43-D1F2-47A3-8EC3-4F0D4942B55AQ33820732-BE0EF589-01A8-4159-88E3-BBE9FE281491Q33839464-FF21557F-357E-45DA-A85E-104E7A9804B3Q33907707-32FA479E-56D9-4621-BA2D-0E0856762158Q34350453-701CDDB9-B8FF-4C44-8E80-C0EED19530EEQ35109380-EC86FC30-76FB-43C4-ADEA-8258BEC183AAQ35228549-9B1E5E1B-3589-47BC-AFD5-B856D7D73411Q35235777-02BB9762-4A2A-4CFE-AD39-C27FECB7448CQ35993484-A6B58F20-CE83-4758-9EAA-769253F2FBB2Q36523991-6D6B88C1-FDA3-46CA-96E5-E208C9D3BA1CQ36781677-DE76D53C-2D41-4CB5-95C1-A3E9F9378249Q37266550-D3B63FD4-9D79-4FBC-A4FA-068DB4116E17Q37328641-B928EF73-66B9-42C9-BE6E-B24383C0260AQ37591325-C2D11137-255B-4224-B452-293D6048F9AEQ37678602-F254E4C8-18BC-42D8-B605-D9D5C7DD5270Q39422643-4F209EDE-0E1B-4EB5-BBE4-737693167508Q39810755-0897E34C-1726-40A5-9150-F6606178590FQ40044748-7AD532BA-F52C-48A6-944B-75968591F48EQ40075978-5AED52ED-6633-4673-B1C5-BAA5C9AD07EFQ40201638-E363586A-938A-4039-BC58-CC0F78995DEEQ40334782-D969203D-0B68-44CC-B77B-13E720A56329Q41199980-425D60D2-7B3E-4B50-AA2E-7AEF743348A7Q48828073-D5E96C47-C9B3-492A-88F5-3360F7FEDD78Q57481875-AE2B278C-83FC-4BF0-B120-F3597333E2FA
P2860
Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans.
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年学术文章
@wuu
1976年学术文章
@zh-cn
1976年学术文章
@zh-hans
1976年学术文章
@zh-my
1976年学术文章
@zh-sg
1976年學術文章
@yue
1976年學術文章
@zh
1976年學術文章
@zh-hant
name
Comparative efficacy of neuram ...... dy to neuraminidase in humans.
@en
Comparative efficacy of neuram ...... dy to neuraminidase in humans.
@nl
type
label
Comparative efficacy of neuram ...... dy to neuraminidase in humans.
@en
Comparative efficacy of neuram ...... dy to neuraminidase in humans.
@nl
prefLabel
Comparative efficacy of neuram ...... dy to neuraminidase in humans.
@en
Comparative efficacy of neuram ...... dy to neuraminidase in humans.
@nl
P356
P1476
Comparative efficacy of neuram ...... dy to neuraminidase in humans.
@en
P2093
Kilbourne ED
P304
P356
10.1093/INFDIS/134.4.384
P407
P577
1976-10-01T00:00:00Z